SAMN03290897
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.600
- E2F_TARGETS+0.500
- MYC_TARGETS_V1+0.500
- OXIDATIVE_PHOSPHORYLATION+0.500
- G2M_CHECKPOINT+0.300
- DNA_REPAIR+0.200
- SPERMATOGENESIS+0.200
- ADIPOGENESIS+0.100
- PEROXISOME+0.100
- FATTY_ACID_METABOLISM+0.000
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.600
- ANGIOGENESIS-0.500
- CHOLESTEROL_HOMEOSTASIS-0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.500
- APICAL_SURFACE-0.400
- APOPTOSIS-0.400
- COAGULATION-0.400
- HEDGEHOG_SIGNALING-0.400
- HYPOXIA-0.400
- IL2_STAT5_SIGNALING-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CV-6948-01A-11R-1915-07 | — | — | 0.948 |
| 2 | BS_TZVFR600 | medulloblastoma | — | 0.931 |
| 3 | C3L-00993 | — | cohortSQ1 | 0.927 |
| 4 | SRR5088911 | — | — | 0.926 |
| 5 | MNG81 | — | — | 0.925 |
| 6 | TCGA-UY-A78N-01A-12R-A33J-07 | — | — | 0.922 |
| 7 | TCGA-91-8499-01A-11R-2403-07 | — | cohortMD1 | 0.921 |
| 8 | TCGA-HD-A634-01A-11R-A28V-07 | — | — | 0.920 |
| 9 | BS_NKEAAFMW | medulloblastoma | — | 0.919 |
| 10 | MNG82 | — | — | 0.919 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 9 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.600 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.500 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.500 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.300 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |